Moreover, the CD34+/hCD45+ frequency was reduced (Fig. 7c, e) and the CD15+/hCD45+ cell frequency was increased in miRisten-treated sPDXs (Supplementary Fig. 11a–b), suggesting that miRisten treatment promoted partial differentiation of primitive inv(16) AML cells. The gene discussed is FUT4; the disease is acute myeloid leukemia.